Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
BACKGROUND
Our aim was to determine whether the change in left ventricular (LV) mass in response to antihypertensive treatment could be predicted by multivariate analysis of single nucleotide polymorphisms (SNPs) in candidate genes reflecting pathways likely to be involved in blood pressure control.


METHODS
Patients with mild to moderate primary hypertension and LV hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta1 adrenoreceptor blocker atenolol (n = 49). A microarray-based minisequencing system was used for genotyping 74 SNPs in 25 genes. These genotypes were related to the change in LV mass index by echocardiography, after 12 weeks treatment as monotherapy, using stepwise multiple regression analysis.


RESULTS
The blood pressure reductions were similar and significant in both treatment groups. Two SNPs in two separate genes (the angiotensinogen T1198C polymorphism, corresponding to the M235T variant and the apolipoprotein B G10108A polymorphism) for those treated with irbesartan, and the adrenoreceptor alpha2A A1817G for those treated with atenolol, significantly predicted the change in LV mass. The predictive power of these SNPs was independent of the degree of blood pressure reduction.


CONCLUSIONS
SNPs in the angiotensinogen, apolipoprotein B, and the alpha2 adrenoreceptor gene predicted the change in LV mass during antihypertensive therapy. These results illustrate the potential of using microarray-based technology for SNP genotyping in predicting individual drug responses.
Liljedahl
Ulrika
U
Department of Medical Sciences, Uppsala University, Sweden.
Kahan
Thomas
T
Malmqvist
Karin
K
Melhus
Håkan
H
Syvänen
Ann-Christine
AC
Lind
Lars
L
Kurland
Lisa
L
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000808:Angiotensinogen / Q000235:genetics; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001055:Apolipoproteins B / Q000235:genetics; D001262:Atenolol / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D001794:Blood Pressure / Q000235:genetics*; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000209:etiology; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics; D013777:Tetrazoles / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001055:Apolipoproteins B; D001713:Biphenyl Compounds; D018343:Receptors, Adrenergic, beta-2; D013777:Tetrazoles; D000808:Angiotensinogen; D001262:Atenolol; D000077405:Irbesartan